<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04542590</url>
  </required_header>
  <id_info>
    <org_study_id>DCR-PHXC-502</org_study_id>
    <nct_id>NCT04542590</nct_id>
  </id_info>
  <brief_title>Natural History of Patients With PH3 and a History of Stone Events</brief_title>
  <acronym>PHYOX-OBX</acronym>
  <official_title>A Natural History Study of Patients With Genetically Confirmed Primary Hyperoxaluria Type 3 and, as Applicable Per Age, a History of Stone Events</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dicerna Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dicerna Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a natural history study of adults, adolescents, and children (starting at birth) with&#xD;
      genetically confirmed primary hyperoxaluria type 3 (PH3) who have a history of stone events&#xD;
      during the last 3 years and/or the presence of pre existing stones detected by renal&#xD;
      ultrasound at screening.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The relationship between the level of Uox and the incidence of kidney stones and/or&#xD;
      nephrocalcinosis in patients with PH3 has not been established. The goal of this study is to&#xD;
      record 24-hour Uox levels and the incidence of new stone formation and/or the degree of&#xD;
      nephrocalcinosis in patients with PH3 over time.&#xD;
&#xD;
      Potential participants are screened over an up-to-7 week period according to the eligibility&#xD;
      criteria and will then be followed every 6 months over an up-to-2-year period to determine&#xD;
      the annualized new stone formation rate (number of new stones being formed per year) and the&#xD;
      change in the degree of nephrocalcinosis (if applicable).&#xD;
&#xD;
      New stone formation is defined as occurrence of any of the following:&#xD;
&#xD;
        -  Spontaneous stone passage in the absence of pre-existing stones&#xD;
&#xD;
        -  Stone passage occurring without change in the number of pre-existing stones detected by&#xD;
           renal ultrasound&#xD;
&#xD;
        -  Appearance of new stones on renal ultrasound or 100% or more growth of a pre-existing&#xD;
           stone (estimated area)&#xD;
&#xD;
        -  Surgical removal of newly formed stones Note: Spontaneous passage or surgical removal of&#xD;
           pre-existing stones does not meet the criteria for new stone formation.&#xD;
&#xD;
      This is a non-interventional study that will last up to 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Collect stone formation data in PH3 patients</measure>
    <time_frame>Assess participants' stone formation rates over the course of 2 years</time_frame>
    <description>Collect data on the rate of new stone formation in PH3 patients of at least 2 years of age</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assess relationship between urine oxalate (Uox) levels and stone formations in PH3 patients</measure>
    <time_frame>Measure participants' Uox levels over the course of 2 years</time_frame>
    <description>Explore the potential relationship between Uox levels and new stone formation in patients (≥ 2 years of age) with genetically confirmed PH3 and relatively intact renal function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Collect data on the degree of nephrocalcinosis in PH3 patients</measure>
    <time_frame>Assess the change in nephrocalcinosis grade over the course of 2 years</time_frame>
    <description>Collect data on the degree of nephrocalcinosis in PH3 patients of at least 2 years of age</description>
  </primary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Primary Hyperoxaluria Type 3</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This is a natural history study in adults, adolescents, and children (starting from birth)&#xD;
        with genetically confirmed PH3 who have a history of stone events during the last 3 years&#xD;
        and/or the presence of preexisting stones detected by renal ultrasounds at Screening, and&#xD;
        an eGFR &gt; 30 mL/min/1.73 m2 or serum creatinine below the 97th percentile for patients&#xD;
        younger than 12 months old.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key inclusion criteria&#xD;
&#xD;
          -  Genetically confirmed PH3&#xD;
&#xD;
          -  For participants at least 2 years of age, history of stone events (defined as presence&#xD;
             of calcifications in the urinary tract and/or kidney, their relative location, and the&#xD;
             number and size of stones) during the last 3 years and/or presence of pre-existing&#xD;
             stones detected by renal ultrasound at Screening&#xD;
&#xD;
          -  Uox ≥ 0.7 mmol/24 hours (adjusted per 1.73 m2 BSA in participants &lt; 18 years of age)&#xD;
             OR if not able to collect 24-hour urine, average spot Uox to creatinine ratio at&#xD;
             Screening above the 95th percentile for age:&#xD;
&#xD;
               -  &gt; 220 mmol/mol in participants &lt; 6 months&#xD;
&#xD;
               -  &gt; 170 mmol/mol in participants from 6 months to &lt; 12 months&#xD;
&#xD;
               -  &gt; 130 mmol/mol in participants 12 months to &lt; 2 years&#xD;
&#xD;
               -  &gt; 100 mmol/mol in participants from 2 to &lt; 3 years and&#xD;
&#xD;
               -  &gt; 80 mmol/mol in participants from 3 to 5 years&#xD;
&#xD;
          -  eGFR at Screening ≥ 30 mL/min or for infants aged less than 12 months, serum&#xD;
             creatinine below the 97th percentile of a healthy population&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Prior or planned liver transplant within study period&#xD;
&#xD;
          -  Currently receiving dialysis or anticipating dialysis during study period&#xD;
&#xD;
          -  Unwillingness to comply with study procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra Haagensen, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Dicerna Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Medical Info</last_name>
    <phone>617-621-8097</phone>
    <email>medicalinfo@dicerna.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Bonn</city>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Warsaw</city>
        <zip>04-141</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Lebanon</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 9, 2020</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>primary hyperoxaluria</keyword>
  <keyword>PH3</keyword>
  <keyword>observational</keyword>
  <keyword>kidney stones</keyword>
  <keyword>nephrocalcinosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperoxaluria, Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

